High-impact radiopeptide therapy halts neuroendocrine cancer
Monday, June 6, 2011 - 13:30
in Health & Medicine
Research introduced at SNM's 58th Annual Meeting could be a sign of hope for patients with neuroendocrine cancer not responding well to standard therapies. Most radiotherapies use medical isotopes that emit beta radiation. The therapy in this study employs alpha particles, which have potential for higher potency. In fact, one single atom could be enough to kill an entire cancer cell.